News &amp; Updates

Immediate and delayed autologous breast reconstruction yield similar rates of complications in the context of postmastectomy radiation therapy (PMRT), a new meta-analysis reports.

Immediate, delayed breast reconstruction equally safe

Threatened abortion in utero carries heightened risk of cerebral palsy

Children affected by threatened abortion in utero are at risk of having cerebral palsy but not epilepsy or attention-deficit/hyperactivity disorder, a study has found.

Threatened abortion in utero carries heightened risk of cerebral palsy

Original New Drug Application Approvals by US FDA (16 - 30 April 2021)

New drug applications approved by US FDA as of 16-30 April 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 April 2021)

Weight loss lowers risk of NAFLD in metabolically healthy, overweight people

Metabolically healthy individuals who are overweight or obese may do well to shed a significant amount of weight, as this reduces the risk of developing nonalcoholic fatty liver disease (NAFLD) with or without intermediate or high probability of advanced fibrosis, a study has found.

Weight loss lowers risk of NAFLD in metabolically healthy, overweight people

Sex, physical activity, medications linked to falls in young adults

Among young adults, medications taken, sex, and physical activity levels all affect the risk of falls, a recent study suggests.

Sex, physical activity, medications linked to falls in young adults

Nivolumab-platinum chemo combo improves response in early NSCLC

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Nivolumab-platinum chemo combo improves response in early NSCLC

Dapagliflozin cuts CV events even in sickest kidney disease patients

The SGLT2 inhibitor (SGLT2i) dapagliflozin consistently reduces cardiovascular (CV) events regardless of baseline kidney function and albuminuria status in patients with type 2 diabetes (T2D) — with the greatest absolute benefit in those with most severe kidney disease, according to a prespecified secondary analysis of the DECLARE-TIMI* 58 trial.

Dapagliflozin cuts CV events even in sickest kidney disease patients

RAS inhibitors more renoprotective than CCBs in advanced chronic kidney disease

In the treatment of patients with advanced chronic kidney disease, use of renin-angiotensin system (RAS) inhibitors slows the progression of kidney disease compared with calcium channel blockers (CCBs), although the two drugs offer similar cardiovascular protection, as shown in a study.

RAS inhibitors more renoprotective than CCBs in advanced chronic kidney disease

What effects do glycaemic responses have on cognition, mood, satiety?

Glycaemic response appears to have no impact on cognitive performance, mood, or satiety, as indicated by evidence in a randomized double-blind crossover trial.

What effects do glycaemic responses have on cognition, mood, satiety?

Ivermectin, HCQ prophylaxis fall short of reducing COVID-19 infection, mortality

The efficacy of ivermectin in reducing the risk of SARS-CoV-2 infection remains highly uncertain due to serious risk of bias and imprecision of trials, according to the results of a living systematic review and network meta-analysis.

Ivermectin, HCQ prophylaxis fall short of reducing COVID-19 infection, mortality